Navarra Innoup’s Nanotech Peanut Allergy Vaccine
“`html
Peanut Allergy vaccine Developed Using Nanotechnology Shows Promise
Table of Contents
- Peanut Allergy vaccine Developed Using Nanotechnology Shows Promise
- Peanut Allergy Vaccine: Your Questions Answered
- What is the new peanut allergy vaccine?
- How does the peanut allergy vaccine work?
- Where are clinical trials being conducted?
- What are the phases of clinical trials?
- What where the results of phase I?
- How many people are affected by peanut allergies?
- Why is a peanut allergy a growing concern?
- Who is leading this research?
- What is the role of nanotechnology in this vaccine?
- How is the vaccine administered?
- What is the expected duration of protection?
- What are the potential future implications of this vaccine?
- Key Features and Potential benefits of the peanut Allergy Vaccine
- How can I participate in the clinical trial?
NAVARRA, Spain (AP) — A biotechnology company based in Navarra, Innoup Farma, has announced the development of a potential first-in-the-world vaccine aimed at curing peanut allergies.The treatment uses nanotechnology to stimulate the immune systems of allergic individuals, promoting tolerance to peanut proteins and offering a potentially safer and more effective alternative to current management strategies.
Clinical Trials Underway
The University of Navarra Clinic (CUN) and the Navarra University Hospital (HUN) are currently conducting clinical trials of the vaccine, which are structured in three phases. Researchers are actively seeking new participants following the approval of Phase II by the Spanish Agency for Medicines and health Products. To date,49 patients are participating in the clinical trial,with the collaboration of the Spanish Association of People with Allergy to Food and Latex (AEPNAA).
Peanut Allergy: A Growing concern
According to the Spanish Agency for Food and Nutrition Security (AESAN), peanuts are a leading cause of severe allergic reactions and food-induced anaphylaxis, which can be fatal. In Spain,more than 200,000 people are affected by peanut allergies.Across Europe, the figure is estimated to exceed 11 million. The increasing prevalence of peanuts as ingredients in processed foods has heightened exposure,particularly among children.
Promising results from Phase I
During phase I of the clinical trial, the INP20 oral vaccine was administered to patients, yielding promising initial results. Currently, there is no approved treatment for food allergies, a condition affecting over 220 million people globally and a primary cause of anaphylaxis-related deaths in adolescents.
Dr. Marta Ferrer, a specialist in the department of Allergology at CUN, commented on the progress: “We are facing a progress of great importance in the approach of food allergies. This vaccine does not only seek to reduce the symptoms,but to modify the immune response of the patient from the root. If the results are confirmed, we will be before an inflection point in the treatment of these pathologies.” Dr.Ana tabar, allergologist and principal investigator at HUN, is also a lead researcher in the clinical trial.
Nanotechnology: The Key to Tolerance
The new treatment leverages nanotechnology patented by Innoup Farma to target and regulate immune system cells. Maite agüeros, CEO of Innoup Farma and a Doctor of Pharmacy, explained the mechanism: “The key is to reprogram the patient’s immune system to stop identifying peanut proteins as a threat and can tolerate it without triggering an allergic reaction.”
Nanotechnology optimizes the delivery of active drugs and molecules. Innoup Farma encapsulates a peanut extract containing all allergenic proteins within nanoparticles approximately 200 nanometers in size. This process masks the allergen, causing the immune system to perceive it as non-threatening.
Oral Administration and Long-Term Protection
The oral formulation allows nanoparticles to adhere to the intestinal mucosa, interacting with immune system cells in the intestine.This interaction generates markers that develop an immune response through blocking antibodies, curbing the allergic reaction and fostering allergen tolerance. Daily administration of the vaccine over several months is intended to provide prolonged protection. The nanoparticle mechanism aims to provide long-term protection even after the treatment concludes.
future Implications
The potential success of the INP20 vaccine extends beyond peanut allergies, potentially paving the way for new treatments for other food allergies. Dr. Tabar emphasized the importance of the research: “Being part of this essay represents a real opportunity that will offer a future with more therapeutic options for millions of people. Our goal is to offer a non -invasive treatment that not only protects in front of serious reactions, but also allows you to live with greater freedom and tranquility,” urging more individuals with peanut allergies to participate in the upcoming Phase II trial.
Peanut Allergy Vaccine: Your Questions Answered
What is the new peanut allergy vaccine?
A biotechnology company based in Navarra, Spain, Innoup Farma, has developed a potential first-in-the-world vaccine for peanut allergies. The treatment uses nanotechnology to help people develop tolerance to peanuts.
How does the peanut allergy vaccine work?
The vaccine, named INP20, uses nanotechnology to “reprogram” a patientS immune system. This means it aims to stop the body from identifying peanut proteins as a threat. Innoup Farma encapsulates peanut extract (containing all allergenic proteins) within nanoparticles about 200 nanometers in size. This masks the allergen, causing the immune system to perceive it as non-threatening and, thus, not trigger an allergic reaction.The oral formulation allows nanoparticles to interact with immune system cells in the intestine, which generates markers that develop an immune response through blocking antibodies, curbing the allergic reaction and fostering allergen tolerance.
Where are clinical trials being conducted?
Clinical trials are currently underway at the University of Navarra Clinic (CUN) and the navarra University Hospital (HUN) in Spain.
What are the phases of clinical trials?
The clinical trials are structured in three phases.
What where the results of phase I?
Phase I of the clinical trial yielded promising initial results.
How many people are affected by peanut allergies?
Globally, over 220 million people are affected by food allergies. In Spain, over 200,000 people have peanut allergies, and across Europe, the figure is estimated to exceed 11 million.
Why is a peanut allergy a growing concern?
Peanuts are a leading cause of severe allergic reactions and food-induced anaphylaxis. The increasing prevalence of peanuts as ingredients in processed foods, especially among children, contributes to the growing concern.
Who is leading this research?
- Dr. Marta Ferrer, specialist in the department of Allergology at CUN.
- Dr.Ana Tabar, allergologist and principal investigator at HUN.
What is the role of nanotechnology in this vaccine?
Nanotechnology is the key to the vaccine’s effectiveness. It optimizes the delivery of active drugs and molecules. Innoup Farma uses it to encapsulate a peanut extract within nanoparticles. This encapsulation “masks” the allergen, helping the immune system to develop tolerance rather than triggering an allergic response. the oral administration further allows for interaction with immune cells in the intestine, which helps generate blocking antibodies, and ultimately, curbing the allergic reaction.
How is the vaccine administered?
the vaccine is administered orally. The oral formulation enables the nanoparticles to adhere to the intestinal mucosa.
What is the expected duration of protection?
Daily administration of the vaccine over several months is intended to provide prolonged protection. The nanoparticle mechanism aims to provide long-term protection, even after the treatment concludes.
What are the potential future implications of this vaccine?
The success of the INP20 vaccine could pave the way for new treatments for othre food allergies. This represents a real opportunity that will offer more therapeutic options for millions of people, leading to a non-invasive treatment that protects against serious reactions.
Key Features and Potential benefits of the peanut Allergy Vaccine
Here’s a summary of the key features and, potential benefits, of the INP20 peanut allergy vaccine:
| Feature | Benefit |
|---|---|
| Uses Nanotechnology | Optimizes drug delivery, and masks the allergen to promote tolerance |
| Oral Administration | Allows nanoparticles to interact with the intestinal mucosa |
| Long-Term Protection (Potential) | Aims to offer prolonged protection even after treatment is finished |
| Targets Immune Response | Reprograms the immune system to tolerate peanut proteins |
| Potential beyond Peanut Allergies | Could lead to treatments for other food allergies |
How can I participate in the clinical trial?
Individuals with peanut allergies are urged to participate in the upcoming Phase II trial.Contact data or instructions for participation are not provided in the source content.Further investigation would be required.